NovoCure/$NVCR
1D1W1MYTD1Y5YMAX
Capital at risk
About NovoCure
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
- Ticker
- $NVCR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,605
- Headquarters
- Baar, Switzerland
- Website
- www.novocure.com
NovoCure Metrics
BasicAdvanced
$1.9B
-
-$1.31
0.93
-
Price and volume
Market cap
$1.9B
Beta
0.93
52-week high
$21.45
52-week low
$9.82
Average daily volume
1.2M
Financial strength
Current ratio
2.893
Quick ratio
2.657
Long term debt to equity
0.69
Total debt to equity
0.69
Interest coverage (TTM)
-6.80%
Profitability
EBITDA (TTM)
-136.393
Gross margin (TTM)
76.37%
Net profit margin (TTM)
-21.25%
Operating margin (TTM)
-21.62%
Effective tax rate (TTM)
2.70%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-9.26%
Return on equity (TTM)
-43.22%
Valuation
Price to revenue (TTM)
2.711
Price to book
5.75
Price to tangible book (TTM)
5.75
Price to free cash flow (TTM)
-74.519
Free cash flow yield (TTM)
-1.34%
Free cash flow per share (TTM)
-0.224
Growth
Revenue change (TTM)
10.95%
Earnings per share change (TTM)
-16.16%
3-year revenue growth (CAGR)
11.26%
10-year revenue growth (CAGR)
29.60%
3-year earnings per share growth (CAGR)
-7.52%
10-year earnings per share growth (CAGR)
-4.31%
What the Analysts think about NovoCure
Analyst ratings (Buy, Hold, Sell) for NovoCure stock.
Analyst projections of the future price of NovoCure stock.
Bulls say / Bears say
Q2 2026 net revenues reached $183.6 million, up 16% year-over-year, driven by 18% growth in active patients to a record 5,128, marking the company’s strongest quarter to date (SEC.gov)
Adjusted EBITDA turned positive at $10.8 million in Q2, a significant turnaround from prior losses and a key milestone on its path to profitability (SEC.gov)
Following the strong Q2 performance, NovoCure raised full-year 2026 net revenue guidance to $710 million–$725 million (from $690 million–$710 million) and secured a CE Mark for Optune Pax in pancreatic cancer, expanding its market in the EU with Germany as the first launch (SEC.gov)
Phase 3 TRIDENT failed to meet its primary endpoint of improved overall survival in newly diagnosed glioblastoma, undermining confidence in Novocure’s core GBM franchise and prompting a significant pipeline reset (Reuters)
NovoCure reported a net loss of $15.7 million in Q2 2026 despite positive EBITDA, indicating ongoing cash burn and pressure on the path to sustainable profitability (SEC.gov)
The reported 78% gross margin for Q2 benefited from a one-time $4.9 million tariff refund, raising concerns over the sustainability of its margin improvements absent similar one-off benefits (SEC.gov)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2026.
NovoCure Financial Performance
Revenues and expenses
NovoCure Earnings Performance
Company profitability
Upcoming events
No upcoming events
NovoCure News
AllArticlesVideos
Funds containing NovoCure
AllUSDEURGBP
Fund name | Fund size | $NVCR weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.18% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.18% |
iShares Healthcare Innovation£DRDR | £1B | 0.18% |
iShares Ageing Population€AGED | €822M | 0.15% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.